# Kyriakos P. Papadopoulos

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kyriakos-p-papadopoulos/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,194 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 64 |
| i10-index | 206 |
| Last Known Institution | South Texas Accelerated Research Therapeutics |
| OpenAlex ID | https://openalex.org/A5022467575 |
| ORCID iD | https://orcid.org/0000-0002-0667-2620 |
| Works | 764 |

## Researcher papers

- [Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors](https://scholariq.org/papers/efficacy-and-safety-of-abemaciclib-an-inhibitor-of-cdk4-and-cdk6-for-patients/)
- [Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors](https://scholariq.org/papers/phase-i-study-of-ro4929097-a-gamma-secretase-inhibitor-of-notch-signaling-in/)
- [First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas](https://scholariq.org/papers/first-in-human-phase-i-study-of-copanlisib-bay-80-6946-an-intravenous-pan-class/)
- [First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors](https://scholariq.org/papers/first-in-human-study-of-amg-820-a-monoclonal-anti-colony-stimulating-factor-1/)
- [MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer](https://scholariq.org/papers/mrtx1719-is-an-mta-cooperative-prmt5-inhibitor-that-exhibits-synthetic-lethality/)
- [Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study](https://scholariq.org/papers/datopotamab-deruxtecan-in-advanced-or-metastatic-hr-her2-and-triple-negative/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [South Texas Accelerated Research Therapeutics](https://scholariq.org/institutions/south-texas-accelerated-research-therapeutics/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.